New biosimilar AVT80 compared to entyvio in healthy adults
Knowledge-focused
Completed
This completed Phase 1 study tested a new biosimilar called AVT80 against the approved drug Entyvio in 385 healthy adults aged 18 to 55. The goal was to see how similarly the body processes each drug, and to check safety and immune reactions. Participants received a single inject…
Phase: PHASE1 • Sponsor: Alvotech Swiss AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC